# Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer

> **NCT00113789** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 21 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **OTHER:** PI Discretion

## Key facts

- **NCT ID:** NCT00113789
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2009-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113789, "Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00113789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*